Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis.

Abstract

BACKGROUND:

The combination of transarterial chemoembolization (TACE) and apatinib has been used in the treatment of intermediate or advanced hepatocellular carcinoma (HCC). However, its effectiveness and safety are also argued.

METHODS:

Eligible studies were collected from a computer search of literatures published from the database establishment to May 2019 in PubMed, Web of Science, EMBASE, Ovid, the Cochrane Library, Wanfang Database, China National Knowledge Infrastructure, and China Biology Medicine Disc. The objective response rate (ORR), the disease control rate (DCR), survival rate (SR), and the incidences of treatment-related adverse effects (AEs) were collected as the relevant outcomes. Data were analyzed through fixed/random effects of meta-analysis models with RevMan 5.3 software.

RESULTS:

Eight randomized controlled clinical trials comprising 528 patients and 4 cohort studies comprising 226 patients were eventually included. Compared to the control group treated with TACE solely, combination therapy group, in which intermediate or advanced HCC patients were treated with TACE and apatinib, significantly enhanced ORR (relative risk [RR] 2.06, 95% CI 1.63-2.61, p < 0.001), DCR (RR 1.65, 95% CI 1.24-2.20, p < 0.001), and whole SRs of 6-month (RR 1.52, 95% CI 1.08-2.14, p = 0.02), 1-year (RR 1.52, 95% CI 1.25-1.84, p < 0.001), and 2-year (RR 1.84, 95% CI 1.34-2.54, p < 0.001). The incidence of hand foot syndrome, proteinuria, hypertension, and diarrhea was significantly increased in the combination therapy group compared with the control group (p < 0.05), and the incidence of nausea and vomiting, fever, and myelosuppression, respectively, was similar in 2 groups (p > 0.05).

CONCLUSIONS:

The combination therapy of TACE and apatinib can enhance the clinical effectiveness better than TACE solely in patients with intermediate or advanced HCC, while increase in the AEs is usually tolerable.

• Authors: Yan Wei, Jianjun Liu, Min Yan, Shuguang Zhao, Yong Long, Weilu Zhang
• Journal: Chemotherapy (Chemotherapy) Vol. 64 Issue 2 Pg. 94-104 ( 2019) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 31569090 (Publication Type: Journal Article, Meta-Analysis, Review)
• Copyright: © 2019 S. Karger AG, Basel.

Chemical References

• Protein Kinase Inhibitors
• Pyridines
• apatinib

Topics

• Carcinoma, Hepatocellular (mortality, therapy)
• Chemoembolization, Therapeutic
• Humans
• Liver Neoplasms (mortality, therapy)
• Protein Kinase Inhibitors (therapeutic use)
• Pyridines (therapeutic use)
• Risk
• Survival Rate
• Treatment Outcome